Pamela Carroll Appointed Nutley Oncology Discovery Site Head and Global Head, Pathways Biology at Roche

NUTLEY, N.J., Nov. 7, 2011 /PRNewswire/ -- Roche announced today that Pamela Carroll, PhD, has joined the company as Nutley Oncology Discovery Site Head and Global Head, Pathways Biology within Pharma Research and Early Development (pRED). Pam joins Roche from Belfer Institute of Applied Cancer Sciences at Dana Farber Cancer Institute, Harvard Medical School, where she was Head of Research and a member of the Senior Leadership Team. 

As Oncology Discovery Site Head for Nutley, Pam will be responsible for designing and implementing research studies focused on new or improved oncology medicines, including small molecules and biologics. She will also direct drug discovery research, help develop oncology objectives for Nutley and contribute to the development of the global Discovery Oncology strategy. As Pathways Biology Head, Pam will also assume global responsibility for pathway validation efforts. In close alignment with other key leaders in the Oncology Discovery and Translational Area (DTA) and supporting functions, she will ensure that the Oncology DTA develops robust preclinical models to evaluate pathways, has a strategy to understand their relevance and thoroughly investigates cross-DTA opportunities. 

"With more than a decade's industry experience concentrated in cancer, Pam has built a reputation for scientific excellence and leadership in the field," said Mike Burgess, MD, PhD, Global Head Oncology DTA and Head, Large Molecule Research at Roche. "Her broad knowledge and successful history in leading oncology drug discovery efforts make her is an ideal fit for this position." 

"Roche Oncology is legendary in courageous research that has revolutionized drug development paradigms, and more importantly, improved disease outcomes," said Pam Carroll. "I am honored to join the Roche team during this exciting and historic time in cancer discovery and clinical development." 

Pam has extensive cancer drug discovery experience, ranging from target discovery to preclinical support of development programs. Her research has focused on integrating cancer genetics, genomics and tumor microenvironment biology with mechanistic insights in the development of molecules directed at cancer cell signaling and developmental pathways. Pam has led teams that developed multiple projects currently in clinical trials including Ridaforolimus (mTOR inhibitor), Dalotuzumab (IGF-1R mAB) and MK-0752 (Notch inhibitor). In addition, she has led several multi-year alliances with leading biotechnology companies including AVEO Pharmaceuticals and Exelixis.

Pam has a strong interest in developing innovative models of drug discovery and development by integrating the strengths of pharma, biotech and academic structures. She has served on academic committees or boards at Princeton, University of Arizona and Boston University as well as the Massachusetts Biotech Council. She is a consultant with several biotechnology and venture capital companies. Pam received her BA degree in Biology from Saint Michael's College in Colchester, Vermont, and earned her PhD from Stony Brook University. She then moved across the country to do her Postdoctoral Fellowship in the Department of Biology at Stanford University. In 1999, Pam began her industry career at Bristol Myers Squibb in the Department of Applied Genomics, where she was promoted three times in five years. Her next job was with Merck Research Laboratories, first as Senior Research Fellow/Director and Department Head, Target Validation and then as Director and Department Head, Cancer Pathways. In 2009, she took her most recent position with Belfer, where she built the Institute's innovative concept into a full-fledged, integrated scientific enterprise, and developed and managed successful collaborations with Merck and Sanofi.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

SOURCE Roche